🇺🇸 LGND — Ligand Pharmaceuticals Incorporated

Salud Compra fuerte
← Volver

Precio actual

307,02 USD

Máx. histórico

322,75

3 días

Split 1603:1000 del 02/11/2022

Caída desde máximo

-4,87%

Rango 52 semanas

175,89 – 326,63

Variación hoy

-4,87%

Cierre anterior

322,75

Rango de hoy

306,17 – 324,95

Volumen hoy

265.433

Peor caída histórica

-93,34%

06/03/2000 → 19/11/2008

Recuperado en 2694 días

Volatilidad anualizada ⓘ

59,76%

Información
Nombre completo
Ligand Pharmaceuticals Incorporated
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Biotechnology
Empleados
47
PER ⓘ
32,35 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
350,92 USD (puede no estar actualizado)
Primera cotización
18/11/1992
Precio actualizado
hace 14 horas
Sobre la empresa

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Dividendos repartidos Total últimos 12 meses: 0,0000 USD · Yield: 0,00%
Fecha de pago Importe por participación
03/04/2007 9,3575 USD
Splits Registrados en el histórico de precios
Fecha Ratio
02/11/2022 1603:1000
19/11/2010 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/03/2026 195,65 197,83 188,67 192,64 -1,45% 4,68% 215.400
27/03/2026 202,17 205,87 194,44 195,48 -4,04% 5,65% 268.300
26/03/2026 204,99 207,89 202,30 203,70 -0,42% 2,73% 214.300
25/03/2026 203,17 208,89 201,28 204,56 +1,44% 3,75% 140.300
24/03/2026 200,88 202,07 195,45 201,66 +0,65% 3,30% 214.700
23/03/2026 208,33 214,29 199,74 200,36 -2,17% 6,98% 263.600
20/03/2026 213,20 214,27 204,02 204,81 -2,70% 4,81% 468.300
19/03/2026 207,43 214,45 206,92 210,49 +0,46% 3,63% 149.300
18/03/2026 209,83 213,21 201,94 209,52 -0,70% 5,37% 192.800
17/03/2026 208,00 213,31 205,47 210,99 +1,54% 3,77% 274.700
16/03/2026 204,30 210,42 204,30 207,80 +2,41% 3,00% 211.800
13/03/2026 211,48 214,80 200,69 202,91 -4,05% 6,67% 273.400
12/03/2026 218,80 220,09 196,17 211,48 -4,41% 10,93% 451.400
11/03/2026 217,41 227,92 211,00 221,24 +4,22% 7,78% 386.200
10/03/2026 205,76 216,21 205,49 212,29 +1,98% 5,21% 275.200
09/03/2026 201,68 209,60 198,73 208,16 +3,10% 5,39% 167.000
06/03/2026 202,53 204,26 196,36 201,90 -2,12% 3,90% 188.600
05/03/2026 206,43 208,87 199,00 206,27 -1,28% 4,78% 260.200
04/03/2026 204,85 209,23 198,37 208,95 +2,31% 5,30% 189.200
03/03/2026 198,00 206,08 195,83 204,24 +0,83% 5,18% 176.100
02/03/2026 197,20 204,57 197,20 202,55 +2,14% 3,74% 184.300
27/02/2026 196,17 202,01 194,64 198,31 +1,09% 3,76% 208.700
26/02/2026 191,03 199,06 178,72 196,17 +2,50% 10,65% 256.600
25/02/2026 189,87 193,34 189,04 191,39 +1,26% 2,26% 128.200
24/02/2026 187,00 191,31 183,60 189,00 +2,91% 4,12% 160.900
23/02/2026 183,23 185,18 179,46 183,65 -0,18% 3,12% 159.600
20/02/2026 185,90 186,55 182,51 183,98 -1,26% 2,17% 163.800
19/02/2026 189,54 189,54 183,92 186,32 -1,91% 2,97% 134.700
18/02/2026 186,67 192,46 186,18 189,94 +1,30% 3,36% 180.500
17/02/2026 184,02 189,75 184,02 187,51 +2,00% 3,11% 123.400